BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Expecto Health Science Expands Asia-Pacific Presence with Strategic Partnership with Mayapada Healthcare in Indonesia

January 23, 2025 | News

Expecto Health Science has inked a strategic partnership with Indonesia's Mayapada Hospital to enhance its ability to offer flexible and efficient clinical trial services in Asia and to provide seamless access to high-quality trial sites and patient populations to their global pharma and biotech clients



Expecto Health Science, a leading full-service Contract Research Organization (CRO) in Asia Pacific with a focus on emerging economies, announced the signing of a pivotal Memorandum of Understanding (MOUs) with Mayapada Hospital Jakarta Selatan, a flagship hospital unit by Mayapada Healthcare. This milestone marks a key step in Expecto Health Science's strategy to expand its high-quality, agile clinical research services across the Asia-Pacific region. The partnership was formalized by Dr Pramod Kashid, Chief Executive Officer and Simon Wong, Chief Business Officer, Expecto Health Science, Dr. Dini Handayani, MARS, FISQua, FIPC, Chief Medical Officer, of Mayapada Healthcare and Dr. Fiktorius Kuludong, MM, Director, of Mayapada Hospital Jakarta Selatan. The signing ceremony was held on Friday 17 th January at Mayapada Hospital Jakarta Selatan, Indonesia in the presence of hospital executives, clinicians and Mayapada's Clinical Research Manager and executives.

Expecto Health Science, CEO, Dr. Pramod Kashid cited the collaboration as a major regional expansion and an important step towards clinical research capacity building. "As Expecto Health Science continues to grow its regional footprint, partnerships with respected institutions, like Mayapada Healthcare will further enhance our ability to offer flexible, efficient, and high-quality clinical trial services in the Asia-Pacific region. With its large and diverse patient population, high burden of disease, potential for faster recruitment, growing healthcare infrastructure and government initiatives and support, Indonesia offers an ideal environment for clinical trials."

Simon Wong, Expecto's Chief Business Officer, added "This MOU signing will not only solidify our collaboration with Mayapada Healthcare but also provide our global clients with seamless access to high-quality, cost effective clinical trial sites in the region. We look forward to forging deeper connections and driving growth in Indonesia."

Dr. Dini Handayani, MARS, FISQua, FIPC, Chief Medical Officer, Mayapada Healthcare, shared his enthusiasm for the collaboration, remarking, "Partnering with Expecto will help augment Mayapada Hospital's clinical research capabilities regionally and globally, and in turn, Mayapada's clinical research unit will provide professional and medical advice to

Expecto for clinical trials conducted at Mayapada's clinical research sites, including feasibility, site selection and patient recruitment. We believe this collaboration will not only strengthen our capabilities but also enable us to offer cutting-edge therapeutic solutions that will impact patients on a national, regional and global scale."

Expecto will work closely with Mayapada Hospital to ensure early discussions with their Clinical Research Teams, Principal Investigators and Key Opinion Leaders about projects that may be appropriate and beneficial to Indonesia. The MOU also means that leaders in each organisation will have closer direct access to one another and the two organisations will work to ensure rapid engagement and high priority start-up of new clinical projects in the country.